ArticlePloS one2025
Analysis of disease burden and future trends of ischemic heart disease in China and globally, 1990-2023.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative pulmonary infection prevention and management in adult patients after coronary artery bypass grafting: a summary of best evidence.BMC cardiovascular disorders · 2026Pooled it
- Retraction: Analysis of disease burden and future trends of ischemic heart disease in China and globally, 1990-2023.PloS one · 2026Article
- Development and validation of a clinical-ready nomogram for predicting postoperative pulmonary infection after coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Retraction · 2026-06-17Concerns/Issues about Data · Investigation by Journal/Publisher · Investigation by Third Party · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to analyze the characteristics and trends of the disease burden of ischemic heart disease (IHD) in China and worldwide, across different age and sex groups, to provide a comprehensive understanding of the situation in China.
methodsUsing GBD 2023 data, we analyzed global and China-specific IHD incidence, prevalence, mortality, and DALYs. Joinpoint regression was used to assess trends, while factors such as aging and population growth were also examined. An ARIMA model projected the IHD burden from 2024 to 2050.
resultsFrom 1990 to 2023, the age-standardized incidence rate (ASIR) and prevalence rate (ASPR) of IHD in China exhibited an upward trend. The ASIR per 100,000 increased from 109.7 (95% uncertainty interval [UI]: 93-128) to 110.3 (95% UI: 89-131), while the age-standardized mortality rate (ASMR) decreased from 126.8 (95% UI: 92-163) to 109.5 (95% UI: 94-127), mirroring global trends. The highest incidence of IHD was observed in individuals aged 60-89 years, with mortality peaking between 80-89 years. AAPC analysis revealed that China's ASIR (AAPC = -0.091%; 95% CI: -0.152 to -0.029) and ASPR (AAPC = 0.227%; 95% CI: 0.115 to 0.34) increased more rapidly than the global average. Decomposition analysis indicated that the rise in IHD burden in China was primarily driven by population aging and growth, a pattern observed globally. Forecasting models suggest that the ASIR will continue to rise in China through 2050, while the ASMR and age-standardized DALYs rates (ASDR) are expected to decline further.
conclusionThe incidence and prevalence of IHD in China are projected to rise through approximately 2030. Older males bear a disproportionate burden of the disease. More targeted preventive, diagnostic, and therapeutic strategies are urgently needed and should be informed by the findings of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.